Overview

A Phase 1b Study of Lonitoclax + Azacitidine in Acute Myeloid Leukemia Patients

Status:
NOT_YET_RECRUITING
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
This is a clinical study aiming to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ZE50-0134 in relapsed and refractory Acute Myeloid Leukemia patients.
Phase:
PHASE1
Details
Lead Sponsor:
Lomond Therapeutics Holdings, Inc.